Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma - PubMed (original) (raw)
Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma
L G LeMay et al. Cancer Immunol Immunother. 1993 Aug.
Abstract
Twenty-five CD4+ cytotoxic T lymphocyte (CTL) clones were obtained from the peripheral blood or tumor tissues of melanoma patients undergoing active specific immunotherapy. Melanoma-reactive T cells were cloned by limiting dilution using either autologous or allogeneic melanoma cells to stimulate their proliferation. Sixteen of the clones reacted against autologous melanoma cells but not against the autologous lymphoblastoid cell line, which we defined as "melanoma-specific." Optimal demonstration of the lytic activity of CD4+ CTL required a 16-h incubation period and an effector:target cell ratio of 40:1. In addition, a 24-h pre-incubation of the target melanoma cells with 100 U interferon (IFN) gamma consistently augmented lysis by these CD4+ CTL, increasing it from a mean level of 20% to one of 52%. Lysis by 8 of the 11 melanoma-reactive CD4+ T cell clones was exclusively HLA-class-I-restricted, as judged by blocking with monoclonal antibodies (mAb). Five of these HLA class-I-restricted clones were reactive only with the autologous melanoma cells, while the other 3 clones were also reactive with allogeneic melanoma cells. In all cases, the T cells and melanoma targets shared at least one HLA class I allele, usually HLA-A2, HLA-C3 or HLA-B62. Interestingly, lysis by 2 of the 11 clones was inhibited by both anti-HLA-class-I or -HLA-class-II mAb, while lysis by 1 other clone was inhibited by neither. HLA class I molecules and several accessory molecules were maximally expressed by the melanoma target cells, both in terms of distribution and copy number before IFN gamma treatment. Thus, IFN gamma may have acted by increasing the expression of melanoma-associated epitopes as presented by HLA class I (or HLA class II) molecules. A proportion of human CD4+ CTL appeared to recognize melanoma-associated epitopes presented by the HLA class I molecule, although their lytic potency may be less than that of their CD8+ counterparts.
Similar articles
- Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
Kan-Mitchell J, Huang XQ, Steinman L, Oksenberg JR, Harel W, Parker JW, Goedegebuure PS, Darrow TL, Mitchell MS. Kan-Mitchell J, et al. Cancer Immunol Immunother. 1993 Jul;37(1):15-25. doi: 10.1007/BF01516937. Cancer Immunol Immunother. 1993. PMID: 8513449 Free PMC article. - Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma.
Gottlieb DJ, Li YC, Lionello I, Tanzarella S, Marangolo M, Bradstock KF, Russo V, Traversari C. Gottlieb DJ, et al. Br J Cancer. 2006 Jul 17;95(2):181-8. doi: 10.1038/sj.bjc.6603243. Epub 2006 Jul 4. Br J Cancer. 2006. PMID: 16819544 Free PMC article. - CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.
Somasundaram R, Robbins P, Moonka D, Loh E, Marincola F, Patel A, Guerry D, Herlyn D. Somasundaram R, et al. Int J Cancer. 2000 Jan 15;85(2):253-9. doi: 10.1002/(sici)1097-0215(20000115)85:2<253::aid-ijc17>3.0.co;2-u. Int J Cancer. 2000. PMID: 10629086 - Attempts to optimize active specific immunotherapy for melanoma.
Mitchell MS. Mitchell MS. Int Rev Immunol. 1991;7(4):331-47. doi: 10.3109/08830189109114878. Int Rev Immunol. 1991. PMID: 1779176 Review. - T-cell clones that react against autologous human tumors.
Mukherji B, Chakraborty NG, Sivanandham M. Mukherji B, et al. Immunol Rev. 1990 Aug;116:33-62. doi: 10.1111/j.1600-065x.1990.tb00803.x. Immunol Rev. 1990. PMID: 2146210 Review.
Cited by
- Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O, Schulze-Garg C, Warnecke G, Gugel R, Löhler J, Deppert W. Utermöhlen O, et al. J Virol. 2001 Nov;75(22):10593-602. doi: 10.1128/JVI.75.22.10593-10602.2001. J Virol. 2001. PMID: 11602701 Free PMC article. - Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.
Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA. Topalian SL, et al. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9461-5. doi: 10.1073/pnas.91.20.9461. Proc Natl Acad Sci U S A. 1994. PMID: 7937789 Free PMC article. - Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma.
Morisaki T, Morton DL, Uchiyama A, Yuzuki D, Barth A, Hoon DS. Morisaki T, et al. Cancer Immunol Immunother. 1994 Sep;39(3):172-8. doi: 10.1007/BF01533383. Cancer Immunol Immunother. 1994. PMID: 7923247 Free PMC article. - Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
Kan-Mitchell J, Huang XQ, Steinman L, Oksenberg JR, Harel W, Parker JW, Goedegebuure PS, Darrow TL, Mitchell MS. Kan-Mitchell J, et al. Cancer Immunol Immunother. 1993 Jul;37(1):15-25. doi: 10.1007/BF01516937. Cancer Immunol Immunother. 1993. PMID: 8513449 Free PMC article. - Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients.
Kilmartin DJ, Wilson D, Liversidge J, Dick AD, Bruce J, Acheson RW, Urbaniak SJ, Forrester JV. Kilmartin DJ, et al. Br J Ophthalmol. 2001 Mar;85(3):281-6. doi: 10.1136/bjo.85.3.281. Br J Ophthalmol. 2001. PMID: 11222331 Free PMC article.
References
- Basham TY, Merigan TC. Recombinant interferon-γ increase HLA-DR synthesis and expression. J Immunol. 1983;130:1492. - PubMed
- Carrel S, Schmidt-Kessen A, Giuffre L. Recombinant interferon-γ can induce the expression of HLA-DR and -CD on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor associated antigens. Eur J Immunol. 1985;15:118. - PubMed
- Chang JC, Moorhead JW. Hapten-specific, class II-restricted killing by cloned T cells: direct lysis and production of a cytotoxic factor. J Immunol. 1986;136:2826. - PubMed
- Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DAA, Strominger JL. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 1992;358:764. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous